Back to top
more

Sanofi (SNY)

(Delayed Data from NSDQ)

$56.26 USD

56.26
1,669,691

-0.07 (-0.12%)

Updated Aug 30, 2024 04:00 PM ET

After-Market: $56.24 -0.02 (-0.04%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (84 out of 250)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Ritujay Ghosh headshot

5 Stocks in the Spotlight on Trump's Coronavirus Vaccine Optimism

Millions are pinning their hopes on a handful of drugmakers, which are into the final phases of their vaccine trial.

Kinjel Shah headshot

Pharma Stock Roundup: ABBV, MRK Q2 Earnings & Coronavirus Updates in Focus

Sanofi (SNY)/Glaxo (GSK) and J&J (JNJ) sign deals with U.S. government for coronavirus vaccine candidate. Several drugmakers announce second-quarter results.

Novo Nordisk's (NVO) Q2 Earnings Beat Estimates, Sales Miss

Novo Nordisk's (NVO) earnings surpass estimates but revenues miss the same in the second quarter of 2020.

BioMarin (BMRN) Q2 Earnings Top, Sales Show Coronavirus Impact

BioMarin (BMRN) reports better-than-expected second-quarter results. The company maintains its previously issued guidance for 2020.

Regeneron's (REGN) Q2 Earnings & Sales Surpass Estimates

Regeneron (REGN) beats on Q2 earnings and sales on solid performance of Dupixent and oncology drug, Libtayo.

The Zacks Analyst Blog Highlights: Eli Lilly, Moderna, Pfizer, Sanofi, GlaxoSmithKline and BioNTech

The Zacks Analyst Blog Highlights: Eli Lilly, Moderna, Pfizer, Sanofi, GlaxoSmithKline and BioNTech

Ritujay Ghosh headshot

Pharma Stocks in Focus on Late-Stage Coronavirus Vaccine Trials

Hopes of a vaccine have once again started rising with a number of companies now entering the final phase of their trials.

Kinjel Shah headshot

Pharma Stock Roundup: Q2 Earnings & J&J and PFE's Coronavirus Updates in Focus

Pfizer's (PFE) coronavirus vaccine candidate enters phase III. Several drugmakers announce second-quarter results.

Coronavirus Vaccine Efforts Key to Moderna (MRNA) Q2 Earnings

Moderna (MRNA) is progressing with coronavirus vaccine development. The company has initiated a late-stage study and investors will likely focus any preliminary data from the study

What's in the Cards for Regeneron's (REGN) Q2 Earnings?

Investors will focus on the performance of Eylea and Dupixent along with other pipeline updates when Regeneron (REGN) reports second-quarter 2020 results.

Sanofi (SNY) Q2 Earnings Top Estimates, Sales Lag, EPS View Up

Sanofi (SNY) beats Q2 estimates for earnings while missing the same for sales. Gain from COVID-19 associated patient stockpiling in the first quarter reverses in this quarter. Stock up.

Sanofi (SNY) to Report Q2 Earnings: What's in the Cards?

Investor focus is likely to be on the impact of the coronavirus outbreak on Sanofi's (SNY) performance when it reports second-quarter results.

What's in Store for Novavax (NVAX) This Earnings Season?

Novavax (NVAX) is developing a coronavirus vaccine. The company is likely to provide an update on the vaccine's progress on its Q2 earnings call.

Is a Beat in Store for Translate Bio (TBIO) in Q2 Earnings?

On Translate Bio's (TBIO) Q2 earnings call, investor focus will be on the company's progress with the development of its multiple COVID-19 vaccine candidates in collaboration with Sanofi.

Why Sanofi (SNY) is a Great Dividend Stock Right Now

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Sanofi (SNY) have what it takes? Let's find out.

Glaxo, CureVac to Develop mRNA Vaccines for Infectious Disease

Glaxo (GSK) signs a pact with CureVac for the development/commercialization of mRNA-based vaccines and monoclonal antibodies aimed at infectious disease pathogens.

Can Pfizer (PFE) Deliver a Beat in Coronavirus-Hit Q2 Earnings?

Investor focus is likely to be on the extent of the impact of the coronavirus outbreak on Pfizer's (PFE) performance when it reports second-quarter results.

Biogen (BIIB) to Report Q2 Earnings: What's in the Cards?

Investor focus is likely to be on the extent of the impact of the coronavirus outbreak on Biogen's (BIIB) second-quarter earnings.

Sheraz Mian headshot

Top Analyst Reports for Netflix, AstraZeneca & Union Pacific

Today's Research Daily features new research reports on 16 major stocks, including Netflix (NFLX), AstraZeneca (AZN) and Union Pacific (UNP).

Daniel Laboe headshot

What To Expect From The Crazy Earnings Season Ahead

Are Netflix's disappointing results a foreshadowing of what is to come from the most parabolic tech stocks this earnings season?

The Zacks Analyst Blog Highlights: Moderna, BioNTech, Pfizer, GlaxoSmithKline and Sanofi

The Zacks Analyst Blog Highlights: Moderna, BioNTech, Pfizer, GlaxoSmithKline and Sanofi

Tirthankar Chakraborty headshot

Markets Bet Big on Coronavirus Vaccine Stocks: 3 Front Runners

As investors cheer signs of progress in COVID-19 vaccine development, here're three stocks that are worth keeping an eye on.

Ritujay Ghosh headshot

FDA Aims to Fast-Track Coronavirus Vaccine: 3 Stocks in Focus

Vaccine seems to be the only hope now to counter the pandemic given that millions of new cases of coronavirus are being reported every day.

Novo Nordisk's Shares Rise on New Approvals, Strong Portfolio

Shares of Novo Nordisk (NVO) rally on solid product portfolio aided by new approvals.

The Zacks Analyst Blog Highlights: Oracle, Abbott Laboratories, Chevron, Sanofi and Boeing

The Zacks Analyst Blog Highlights: Oracle, Abbott Laboratories, Chevron, Sanofi and Boeing